Tyrosinemia: a review - PubMed (original) (raw)
Review
. 2001 May-Jun;4(3):212-21.
doi: 10.1007/s100240010146.
Affiliations
- PMID: 11370259
- DOI: 10.1007/s100240010146
Review
Tyrosinemia: a review
P A Russo et al. Pediatr Dev Pathol. 2001 May-Jun.
Abstract
Hypertyrosinemia encompasses several entities, of which tyrosinemia type I (or hepatorenal tyrosinemia, HT1) results in the most extensive clinical and pathological manifestations involving mainly the liver, kidney, and peripheral nerves. The clinical findings range from a severe hepatopathy of early infancy to chronic liver disease and rickets in the older child; gradual refinements in the diagnosis and medical management of this disorder have greatly altered its natural course, mirroring recent advances in the field of metabolic diseases in the past quarter century. Hepatorenal tyrosinemia is the inborn error with the highest incidence of progression to hepatocellular carcinoma, likely due to profound mutagenic effects and influences on the cell cycle by accumulated metabolites. The appropriate follow-up of patients with cirrhosis, the proper timing of liver transplantation in the prevention of carcinoma, and the long-term evolution of chronic renal disease remain important unresolved issues. The introduction of a new pharmacologic agent, NTBC, holds the hope of significantly alleviating some of the burdens of this disease. Mouse models of this disease have permitted the exploration of newer treatment modalities, such as gene therapy by viral vectors, including ex vivo and in utero methods. Finally, recent observations on spontaneous genetic reversion of the mutation in HT1 livers challenge conventional concepts in human genetics.
Similar articles
- HCC prevalence and histopathological findings in liver explants of patients with hereditary tyrosinemia type 1.
Seda Neto J, Leite KM, Porta A, Fonseca EA, Feier FH, Pugliese R, Miura IK, Chapchap P, Porta G. Seda Neto J, et al. Pediatr Blood Cancer. 2014 Sep;61(9):1584-9. doi: 10.1002/pbc.25094. Epub 2014 May 22. Pediatr Blood Cancer. 2014. PMID: 24852359 - Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1.
VanLith C, Guthman R, Nicolas CT, Allen K, Du Z, Joo DJ, Nyberg SL, Lillegard JB, Hickey RD. VanLith C, et al. Hum Gene Ther. 2018 Nov;29(11):1315-1326. doi: 10.1089/hum.2017.252. Epub 2018 Jun 22. Hum Gene Ther. 2018. PMID: 29764210 Free PMC article. - Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1.
Morrow G, Tanguay RM. Morrow G, et al. Adv Exp Med Biol. 2017;959:9-21. doi: 10.1007/978-3-319-55780-9_2. Adv Exp Med Biol. 2017. PMID: 28755181 Review. - Autologous Gene and Cell Therapy Provides Safe and Long-Term Curative Therapy in A Large Pig Model of Hereditary Tyrosinemia Type 1.
Hickey RD, Nicolas CT, Allen K, Mao S, Elgilani F, Glorioso J, Amiot B, VanLith C, Guthman R, Du Z, Chen H, Harding CO, Kaiser RA, Nyberg SL, Lillegard JB. Hickey RD, et al. Cell Transplant. 2019 Jan;28(1):79-88. doi: 10.1177/0963689718814188. Epub 2018 Nov 26. Cell Transplant. 2019. PMID: 30477316 Free PMC article. - The Liver in Tyrosinemia Type I: Clinical Management and Course in Quebec.
Halac U, Dubois J, Mitchell GA. Halac U, et al. Adv Exp Med Biol. 2017;959:75-83. doi: 10.1007/978-3-319-55780-9_6. Adv Exp Med Biol. 2017. PMID: 28755185 Review.
Cited by
- New Cases of Maleylacetoacetate Isomerase Deficiency with Detection by Newborn Screening and Natural History over 32 Years: Experience from a German Newborn Screening Center.
Gramer G, Wortmann SB, Fang-Hoffmann J, Kohlmüller D, Okun JG, Prokisch H, Meitinger T, Hoffmann GF. Gramer G, et al. Int J Neonatal Screen. 2024 Feb 27;10(1):17. doi: 10.3390/ijns10010017. Int J Neonatal Screen. 2024. PMID: 38535121 Free PMC article. - Hereditary Tyrosinemia Type 1 Mice under Continuous Nitisinone Treatment Display Remnants of an Uncorrected Liver Disease Phenotype.
Neuckermans J, Lequeue S, Claes P, Heymans A, Hughes JH, Colemonts-Vroninks H, Marcélis L, Casimir G, Goyens P, Martens GA, Gallagher JA, Vanhaecke T, Bou-Gharios G, De Kock J. Neuckermans J, et al. Genes (Basel). 2023 Mar 11;14(3):693. doi: 10.3390/genes14030693. Genes (Basel). 2023. PMID: 36980965 Free PMC article. - Skin-Interfaced Wearable Sweat Sensors for Precision Medicine.
Min J, Tu J, Xu C, Lukas H, Shin S, Yang Y, Solomon SA, Mukasa D, Gao W. Min J, et al. Chem Rev. 2023 Apr 26;123(8):5049-5138. doi: 10.1021/acs.chemrev.2c00823. Epub 2023 Mar 27. Chem Rev. 2023. PMID: 36971504 Free PMC article. Review. - Understanding metabolic alterations after SARS-CoV-2 infection: insights from the patients' oral microenvironmental metabolites.
Ma S, Yang L, Li H, Chen X, Lin X, Ge W, Wang Y, Sun L, Zhao G, Wang B, Wang Z, Wu M, Lu X, Akhtar ML, Yang D, Bai Y, Li Y, Nie H. Ma S, et al. BMC Infect Dis. 2023 Jan 23;23(1):42. doi: 10.1186/s12879-022-07979-y. BMC Infect Dis. 2023. PMID: 36690957 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous